JP2012136542A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136542A5
JP2012136542A5 JP2012045015A JP2012045015A JP2012136542A5 JP 2012136542 A5 JP2012136542 A5 JP 2012136542A5 JP 2012045015 A JP2012045015 A JP 2012045015A JP 2012045015 A JP2012045015 A JP 2012045015A JP 2012136542 A5 JP2012136542 A5 JP 2012136542A5
Authority
JP
Japan
Prior art keywords
seq
rna molecule
sequence
composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012045015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012136542A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012136542A publication Critical patent/JP2012136542A/ja
Publication of JP2012136542A5 publication Critical patent/JP2012136542A5/ja
Pending legal-status Critical Current

Links

JP2012045015A 2004-09-10 2012-03-01 ウィルス遺伝子発現を効率的に阻害する低分子干渉rnaおよびその使用方法 Pending JP2012136542A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60857404P 2004-09-10 2004-09-10
US60/608,574 2004-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007531467A Division JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉rnaおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2012136542A JP2012136542A (ja) 2012-07-19
JP2012136542A5 true JP2012136542A5 (enExample) 2013-05-30

Family

ID=36060681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007531467A Withdrawn JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉rnaおよびその使用方法
JP2012045015A Pending JP2012136542A (ja) 2004-09-10 2012-03-01 ウィルス遺伝子発現を効率的に阻害する低分子干渉rnaおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007531467A Withdrawn JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉rnaおよびその使用方法

Country Status (5)

Country Link
US (4) US20090170794A1 (enExample)
EP (1) EP1793835A4 (enExample)
JP (2) JP2008512500A (enExample)
IL (1) IL190114A0 (enExample)
WO (1) WO2006031901A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031901A2 (en) 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
EP1849865B1 (en) * 2005-01-28 2013-05-22 Haplopharma Inc. RNAi MEDICINE HAVING NO ADVERSE EFFECTS
RU2008114304A (ru) * 2005-09-12 2009-11-20 Сомадженикс Инк. (Us) Ингибирование вирусной экспрессии генов с использованием малой интерферирующей рнк
CA2712056C (en) * 2007-01-16 2016-06-21 The University Of Queensland Method of inducing an immune response
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
JP5149528B2 (ja) * 2007-03-30 2013-02-20 学校法人東京医科大学 C型肝炎ウイルスの複製を制御するマイクロrna
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
US8680064B2 (en) * 2008-09-15 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University ShRNA gene therapy for treatment of ischemic heart disease
CN102245772A (zh) 2008-10-15 2011-11-16 索马根尼科斯公司 抑制基因表达的短发卡rna
CA2747013C (en) * 2008-12-18 2022-05-31 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
EP2443260A4 (en) * 2009-06-19 2012-11-28 Commw Scient Ind Res Org VIRAL ANALYSIS
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
LT2561078T (lt) 2010-04-23 2019-01-10 Cold Spring Harbor Laboratory Naujos struktūriškai sukonstruotos shrnr
CN103328633B (zh) 2010-10-22 2018-07-10 成均馆大学校产学协力团 诱导rna干扰的核酸分子及其用途
US20120308642A1 (en) * 2011-05-27 2012-12-06 Xavier University Of Louisiana Inhibiting hepatitis c viral replication with sirna combinations
JP6137484B2 (ja) * 2011-11-02 2017-05-31 公立大学法人大阪市立大学 遺伝子発現抑制用二本鎖核酸分子
CN110003030A (zh) 2012-02-24 2019-07-12 野草莓树生物制药公司 三烷基阳离子脂质及其使用方法
US10125362B2 (en) 2012-05-22 2018-11-13 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
US10695548B1 (en) * 2013-02-14 2020-06-30 Transderm, Inc. Gene silencing in skin using self-delivery siRNA delivered by a meso device
EP3128008B1 (en) * 2014-04-04 2024-05-29 Bioneer Corporation Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
KR102727666B1 (ko) 2015-11-16 2024-11-08 올릭스 주식회사 MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료
US10519449B2 (en) 2016-02-02 2019-12-31 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
KR102825946B1 (ko) 2016-02-02 2025-06-27 올릭스 주식회사 IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
KR20190108167A (ko) 2017-02-10 2019-09-23 성균관대학교산학협력단 Rna 간섭을 위한 긴 이중가닥 rna
US20230150926A1 (en) 2020-03-17 2023-05-18 Genevant Sciences Gmbh Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
EP4617367A3 (en) 2020-12-18 2025-12-10 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
ES3017428T3 (en) 2022-01-31 2025-05-12 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
WO2003010180A1 (en) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2397062B (en) * 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
JP4228071B2 (ja) * 2003-04-09 2009-02-25 独立行政法人産業技術総合研究所 C型肝炎ウイルスのタンパク質合成及び/又はc型肝炎ウイルスの複製を抑制することができる二本鎖オリゴヌクレオチド
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005028646A1 (ja) * 2003-09-22 2005-03-31 Riken 効率的なdna逆位反復構造の調製方法
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
WO2006031901A2 (en) 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
CN102245772A (zh) * 2008-10-15 2011-11-16 索马根尼科斯公司 抑制基因表达的短发卡rna

Similar Documents

Publication Publication Date Title
JP2012136542A5 (enExample)
Bivalkar-Mehla et al. Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system
Carbonell et al. Multi‐targeting of viral RNAs with synthetic trans‐acting small interfering RNAs enhances plant antiviral resistance
Zheng et al. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome
Alvarez et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy
HRP20190995T1 (hr) LIJEČENJE HBV-a
EA201391394A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
Alabi et al. High‐throughput sequence analysis of small RNA s in grapevine (V itis vinifera L.) affected by grapevine leafroll disease
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
JP2012223202A5 (enExample)
RU2019100094A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
Mollaie et al. RNAi and miRNA in viral infections and cancers
NZ598943A (en) Hbv antisense inhibitors
JP2014527401A5 (enExample)
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
NZ604094A (en) Double stranded rna compounds to rhoa and use thereof
Lin et al. Global analyses of small interfering RNAs derived from Bamboo mosaic virus and its associated satellite RNAs in different plants
WO2013162350A3 (en) Circular antiviral rna
CN115820638B (zh) 一种抑制水禽源禽呼肠孤病毒复制的外源性人工miRNA及其应用
Hemida et al. Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations
Wang et al. Pathogenic roles of m6A modification in viral infection and virus-driven carcinogenesis
JP2010265270A5 (enExample)
JP2010270119A5 (enExample)
Feng et al. In silico analysis the complementarity of tomato microRNA/microRNA* sequences with cucumber mosaic virus (CMV) genomic RNAs
Liu et al. In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide